Patents by Inventor Ulla Hedner

Ulla Hedner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combined use of factor VII polypeptides and factor IX polypeptides
    Publication number: 20030203845
    Abstract: The invention concerns a pharmaceutical preparation comprising a factor VII or factor VII-related polypeptide and a factor IX or factor IX-related polypeptide.
    Type: Application
    Filed: November 12, 2002
    Publication date: October 30, 2003
    Inventors: Jens Bjerre Knudsen, Ulla Hedner, Rasmus Rojkjaer
  • Combined use of VII polypeptides and factor VIII polypeptides
    Publication number: 20030199444
    Abstract: The invention concerns a pharmaceutical preparation comprising a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide.
    Type: Application
    Filed: January 8, 2003
    Publication date: October 23, 2003
    Inventors: Jens Bjerre Knudsen, Ulla Hedner, Rasmus Rojkjaer
  • Pharmaceutical composition comprising a factor VIIa and a factor XIII
    Publication number: 20030092627
    Abstract: The present invention relates to the use of a factor VIIa and a factor XIII in the treatment or prophylaxis of bleeding episodes.
    Type: Application
    Filed: October 15, 2002
    Publication date: May 15, 2003
    Inventors: Lars Christian Petersen, Ulla Hedner, Rojkjaer Rasmus
  • Single-dose administration of factor VIIa
    Publication number: 20030054018
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of Factor VIIa or a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa or Factor VIIa equivalent.
    Type: Application
    Filed: July 16, 2002
    Publication date: March 20, 2003
    Inventor: Ulla Hedner
  • Modified factor VII
    Patent number: 6183743
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The invention relates to novel methods of treatment and uses of modified Factor VII for preventing or treating myocardial injury associated with post-ischemic reperfusion, for improving regional myocardial blood flow during reperfusion, and maintaining or improving vascular patency in a patient, as well as topical application of modified Factor VII at vascular sites susceptible to thrombus formation.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: February 6, 2001
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Charles E. Hart, Lars C. Petersen, Ulla Hedner, Mirella E. Rasmussen
  • Modified factor VII
    Patent number: 6168789
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: January 2, 2001
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Modified Factor VII
    Patent number: 6039944
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: March 21, 2000
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Modified factor VII
    Patent number: 5997864
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The invention relates to novel methods of treatment and uses of modified Factor VII for preventing or treating myocardial injury associated with post-ischemic reperfusion, for improving regional myocardial blood flow during reperfusion, and maintaining or improving vascular patency in a patient, as well as topical application of modified Factor VII at vascular sites susceptible to thrombus formation.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: December 7, 1999
    Assignees: Novo Nordisk A/S, ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Lars C. Petersen, Ulla Hedner, Mirella E. Rasmussen
  • Modified factor VII
    Patent number: 5833982
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: November 10, 1998
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Modified factor VII
    Patent number: 5817788
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
    Type: Grant
    Filed: October 24, 1994
    Date of Patent: October 6, 1998
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Modified factor VII
    Patent number: 5788965
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 4, 1998
    Assignees: Novo Nordisk A/S, ZymoGenetics, Inc.
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard